Belnacasan (VX-765)
中文名称:贝纳卡森
目录号:S2228 Purity: 99.99%
Belnacasan (VX-765)是一种有效的选择性caspase-1抑制剂,无细胞试验中Ki为0.8 nM。Phase 2。
CAS: 273404-37-8
客户使用Selleck的Belnacasan (VX-765)发表文献145篇
- Mol Cancer, 2024 23(1):240
- Drug Resist Updat, 2023 70:100985
- Sci Immunol, 2022 7(68):eabk2092
- Cell Mol Immunol, 2022 19(8):925-943
- Cell, 2020 30;181(3):637-652e15
- Signal Transduct Target Ther, 2020 5(1):235
- Cell, 2018 175(2):442-457
- Immunity, 2018 49(5):842-856
- Nat Commun, 2024 15(1):8266
- Brain Behav Immun, 2024 124:40-54
- EMBO Mol Med, 2024 10.1038/s44321-024-00093-3
- Cell Rep, 2024 43(9):114736
- Cell Mol Life Sci, 2024 81(1):401
- Cell Death Discov, 2024 10(1):156
- Cell Death Discov, 2024 10(1):122
- Ecotoxicol Environ Saf, 2024 290:117549
- PLoS Pathog, 2024 20(8):e1012387
- mBio, 2024 e0330223.
- J Am Heart Assoc, 2024 13(14):e032904
- J Innate Immun, 2024 1-25.
- Am J Cancer Res, 2024 14(3):1338-1352
- J Inflamm (Lond), 2024 21(1):13
- Front Oncol, 2024 14:1438306
- Heliyon, 2024 10(19):e38258
- Anticancer Res, 2024 44(9):3793-3798
- Int J Oral Sci, 2024 16(1):3
- J Exp Clin Cancer Res, 2023 42(1):26
- J Neuroinflammation, 2023 10.1186/s12974-023-02938-z
- J Neuroinflammation, 2023 20(1):41
- Pharmacol Res, 2023 192:106791
- Cell Commun Signal, 2023 10.1186/s12964-023-01359-y
- Cell Biosci, 2023 13(1):87
- Free Radic Biol Med, 2023 202:35-45
- Front Immunol, 2023 14:1149822
- iScience, 2023 26(9):107698
- Int J Mol Sci, 2023 24(14)11692
- Int J Mol Sci, 2023 24(15)11953
- Int J Mol Sci, 2023 24(8)7402
- Parasit Vectors, 2023 16(1):280
- Nat Commun, 2022 13(1):166
- Theranostics, 2022 12(15):6611-6625
- EMBO Mol Med, 2022 e15415
- J Adv Res, 2022 S2090-1232(22)00149-7
- Chemosphere, 2022 S0045-6535(22)02219-6
- Elife, 2022 11e75166
- Elife, 2022 11e73792
- Free Radic Biol Med, 2022 182:171-181
- Front Immunol, 2022 13:832458
- Cancers (Basel), 2022 14(19)4816
- PLoS Pathog, 2022 18(8):e1010787
- J Clin Periodontol, 2022 10.1111/jcpe.13647
- Inflamm Res, 2022 10.1007/s00011-021-01530-6
- Cells, 2022 11(1)134
- Commun Biol, 2022 5(1):47
- Int J Mol Sci, 2022 23(19)11707
- Front Pharmacol, 2022 13:932198
- Front Cell Dev Biol, 2022 10:838785
- Pharmaceutics, 2022 14(7)1495
- J Virol, 2022 96(13):e0016722
- Ann Clin Transl Neurol, 2022 10.1002/acn3.51717
- Cell Signal, 2022 93:110304
- Immunol Lett, 2022 244:28-39
- Food and Chemical Toxicology, 2022 Volume 159
- J Inorg Biochem, 2022 230:111749
- Acta Biochim Biophys Sin (Shanghai), 2022 54(1):64-76
- Microbiol Spectr, 2022 10(3):e0109122
- PLoS One, 2022 17(4):e0257408
- Genes (Basel), 2022 13(11)2133
- Sci Adv, 2022 8(37):eabo0732
- White Rose eTheses Online, 2022
- Sci Transl Med, 2021 13(604)eabb1069
- J Extracell Vesicles, 2021 10(10):e12127
- Redox Biol, 2021 47:102147
- Part Fibre Toxicol, 2021 18(1):10
- Pharmacol Res, 2021 S1043-6618(21)00332-7
- Cell Death Dis, 2021 12(10):871
- Cell Death Dis, 2021 12(1):78
- Cell Rep, 2021 34(10):108756
- Acta Pharmacol Sin, 2021 10.1038/s41401-021-00749-7
- Cell Mol Life Sci, 2021 10.1007/s00018-021-03970-z
- Elife, 2021 10e70938
- Free Radic Biol Med, 2021 166:104-115
- Free Radic Biol Med, 2021 165:171-183
- Front Immunol, 2021 12:753092
- Life Sci, 2021 269:119090
- iScience, 2021 24(10):103170
- Front Cell Dev Biol, 2021 9:779432
- Virulence, 2021 12(1):1362-1376
- Hepatol Commun, 2021 10.1002/hep4.1887
- ACS Chem Neurosci, 2021 12(15):2929-2939
- Food Chem Toxicol, 2021 S0278-6915(21)00805-X
- FEBS Lett, 2021 10.1002/1873-3468.14175
- Vet Microbiol, 2021 258:109126
- BMC Pharmacol Toxicol, 2021 22(1):62
- Immunohorizons, 2021 5(7):602-614
- EMBO J, 2020 18;39(10):e103758
- Cell Rep, 2020 31;30(13):4370-4385e7
- Br J Pharmacol, 2020 28
- Front Pharmacol, 2020 11:541426
- Int J Mol Sci, 2020 21(5)
- Front Microbiol, 2020 11:573844
- Mol Neurobiol, 2020 10.1007/s12035-020-02144-5
- J Mol Cell Cardiol, 2020 138:23-33
- Sci Rep, 2020 24;10(1):7011
- Neurochem Res, 2020 45(2):437-454
- Exp Cell Res, 2020 389(1):111847
- Biochem Biophys Res Commun, 2020 4;526(3):553-559
- Biochem Biophys Res Commun, 2020 522(1):61-67
- Neurourol Urodyn, 2020 39(2):613-624
- Zhongguo Dang Dai Er Ke Za Zhi, 2020 22(9):1027-1033
- Adv Wound Care (New Rochelle), 2020 1;9(5):219-232
- Pharmacol Res, 2019 147:104348
- Cell Prolif, 2019 52(5):e12663
- Int J Nanomedicine, 2019 14:3503-3516
- Front Immunol, 2019 10:268
- Front Immunol, 2019 10:1872
- MBio, 2019 10(1)
- J Cell Physiol, 2019 234(4):4668-4680
- J Cell Physiol, 2019 234(4):3621-3633
- Am J Physiol Cell Physiol, 2019 317(3):C544-C555
- Front Microbiol, 2019 10:2637
- J Mol Cell Cardiol, 2019 138:185-196
- J Immunol, 2019 202(2):550-558
- Toxicol Sci, 2019 10.1093/toxsci/kfz099
- Pediatr Res, 2019 10.1038/s41390-019-0451-3
- Cancer Manag Res, 2019 11:10257-10267
- Parasit Vectors, 2019 12(1):475
- Biochem Biophys Res Commun, 2019 514(4):1066-1073
- Vet Parasitol, 2019 268:16-20
- J Thorac Dis, 2019 11(11):4816-4828
- Nat Commun, 2018 9(1):106
- J Neuroinflammation, 2018 15(1):23
- Mucosal Immunol, 2018 11(4):1191-1202
- Nanomedicine, 2018 14(2):279-288
- Respir Res, 2018 19(1):230
- Sci Rep, 2018 8(1):5667
- Mol Immunol, 2018 104:11-19
- Nan Fang Yi Ke Da Xue Xue Bao, 2018 38(5):567-571
- PLoS Pathog, 2017 13(7):e1006503
- J Cell Mol Med, 2017 21(7):1373-1387
- J Immunol Methods, 2017 447:1-13
- Front Immunol, 2016 7:536
- Oncotarget, 2016 7(51):83951-83963
- Exp Cell Res, 2016 10.1016/j.yexcr.2016.03.009.
- Mucosal Immunol, 2015 9(1):124-36
化学信息&溶解度
分子量 | 509 |
分子式 | C24H33ClN4O6 |
CAS号 | 273404-37-8 |
Smiles | CCOC1C(CC(=O)O1)NC(=O)C2CCCN2C(=O)C(C(C)(C)C)NC(=O)C3=CC(=C(C=C3)N)Cl |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 196.46 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 196.46 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 196.46 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 196.46 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 196.46 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 100 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:5mg/ml
(9.82mM)
操作示例:以 1 mL 工作液为例,取 50 μL 100 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
|
5% DMSO
95% Corn oil
浓度:1.25mg/ml
(2.46mM)
操作示例:以1 mL工作液为例,取50μL 25mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
5% DMSO
40% PEG 300
5%Tween80
50%ddH2O
浓度:5mg/ml
(9.82mM)
操作示例:以1mL工作液为例,取50μL100mg/ml的澄清DMSO储备液加到400μLPEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μLddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。